HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

553.298

-13.196-2.33%

Number of Gainers:5

Number of Losers:25

Number of Flat:4

PE:- -

High:568.474

Open:566.494

Low:545.447

Close:566.494

Loading ...

CFO Yajing Chen Reports Disposal of Common Shares of Zai Lab Ltd

Microport Cardioflow Medtech Corporation Conducted Annual General Meeting

HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 300,000 Shares at HKD 8.1738 Each

Venus MedTech HangZhou Inc. Conducted Annual General Meeting

Ascentage Pharma Announces New Compensation Plan Under 2021 and 2022 RSU Schemes to Reward and Retain Key Talent

Everest Medicines Ltd. Conducted Annual General Meeting

Zylox-Tonbridge Files Next Day Disclosure Return to HKEX: Announces Repurchase of 897,500 Shares at HKD 482,630

Zai Lab Ltd. Announces Resignation of Joint Company Secretary and Appoints New Authorised Representative

Immunotech Biopharm Ltd. Appoints Mr. Yang Xin and Mr. Liu Rui as Non-Executive Directors

JW Cayman Therapeutics Co. Ltd. Held Annual General Meeting

Keymed Biosciences Inc. Conducted Annual General Meeting

Genor Biopharma Delays Financial Reporting Circular Again

Kintor Pharmaceutical Ltd: DR. Youzhi Tong Has Stepped Down as Chairman

THOMSON REUTERS

Kintor Pharmaceutical Ltd. Announces New Leadership for Nomination Committee

Genor Biopharma Holdings Ltd. Conducted Annual General Meeting

RemeGen Grants Development, Sale Rights to Vor Biopharma for Myasthenia Gravis Drug; Shares Plunge 17%

MT Newswires Live

Lu Thai Textile Books 81 Million Yuan Profit From RemeGen Stake Sale

MT Newswires Live

CARsgen Therapeutics Announces Nda Acceptance of Satri-Cel by China's Nmpa

THOMSON REUTERS

CARsgen Therapeutics' New Drug Application for Satricabtagene Autoleucel for Advanced Gastric Cancer Accepted by National Medical Products Administration

CARsgen Therapeutics - Nmpa Accepted New Drug Application for Satricabtagene Autoleucel for Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":553.29803,"timestamp":1751011731363,"preClose":566.4938,"halted":0,"volume":166997278,"delay":0,"changeRate":-0.023294,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-13.19574,"latestTime":"06-27 16:00:00","open":566.4938,"high":568.4741,"low":545.4466,"amount":3865570427,"amplitude":0.040649,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751247000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"pbRate":4.543072,"peRate":-27.983737,"turnoverRate":0.006254,"increases":5,"decrements":26,"flats":2,"marketCap":325335554304,"floatMarketCap":297292501040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":568.4741,"amplitude":0.040649,"preClose":566.4938,"low":545.4466,"pbRate":"4.543072","latestPrice":553.29803,"volume":166997278,"delay":0,"open":566.4938,"prevYearClose":331.1933,"prevWeekClose":541.122,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":541.122,"twentyDayClose":491.683,"sixtyDayClose":459.856,"secType":"PLATE","market":"HK","turnoverRate":0.006254,"peRate":-27.983737,"marketCap":325335554304,"floatMarketCap":297292501040,"timestamp":1751011731363,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":5,"down":25,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546729786","title":"CFO Yajing Chen Reports Disposal of Common Shares of Zai Lab Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2546729786","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546729786?lang=en_us&edition=fundamental","pubTime":"2025-06-28 04:15","pubTimestamp":1751055359,"startTime":"0","endTime":"0","summary":"Chen Yajing, Chief Financial Officer of Zai Lab Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL4yxhDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CFO Yajing Chen Reports Disposal of Common Shares of Zai Lab Ltd","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","09688","BK1574","BK1588","BK1161"],"gpt_icon":0},{"id":"2546741786","title":"Microport Cardioflow Medtech Corporation Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546741786","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546741786?lang=en_us&edition=fundamental","pubTime":"2025-06-27 22:01","pubTimestamp":1751032863,"startTime":"0","endTime":"0","summary":"Microport Cardioflow Medtech Corporation held its annual general meeting on June 27, 2025. All proposed resolutions were approved by the shareholders. The meeting included the retirement of an independent non-executive director and the appointment of Dr. Hu Bingshan as a new independent non-executive director, along with changes in the composition of the board committees.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDLbRkZ6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02160","BK1589","00853","BK1585","BK1574","BK1583","BK1100"],"gpt_icon":0},{"id":"2546418307","title":"HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 300,000 Shares at HKD 8.1738 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2546418307","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546418307?lang=en_us&edition=fundamental","pubTime":"2025-06-27 21:44","pubTimestamp":1751031853,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, reporting the repurchase of 300,000 shares at an aggregate price of HKD 2,452,130. The repurchased shares are being held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDLbRPDGl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","02142","BK1574"],"gpt_icon":0},{"id":"2546749142","title":"Venus MedTech HangZhou Inc. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546749142","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546749142?lang=en_us&edition=fundamental","pubTime":"2025-06-27 21:27","pubTimestamp":1751030849,"startTime":"0","endTime":"0","summary":"Venus MedTech HangZhou Inc. held its 2024 Annual General Meeting on June 27, 2025. During the meeting, all proposed resolutions were approved. The Board elected Mr. Ting Yuk Anthony Wu as the chairman of the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL7VvfgS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02500","BK1100","BK1574","BK1583"],"gpt_icon":0},{"id":"2546466537","title":"Ascentage Pharma Announces New Compensation Plan Under 2021 and 2022 RSU Schemes to Reward and Retain Key Talent","url":"https://stock-news.laohu8.com/highlight/detail?id=2546466537","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546466537?lang=en_us&edition=fundamental","pubTime":"2025-06-27 20:55","pubTimestamp":1751028945,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has announced further grants under its 2021 and 2022 RSU Schemes. The grants include awards for specific 2022 Selected Persons, aimed at rewarding their contributions to the company's growth. Notably, the grant of 2022 Awards to Dr. Zhai has received approval from independent non-executive directors, ensuring compliance with relevant regulations. The vesting of the 2021 Awards is contingent upon the recipients achieving satisfactory annual performance review scores. Additionally, a clawback mechanism is in place, allowing the company to rescind unvested RSUs under certain conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content us","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL7wxQt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2546474575","title":"Everest Medicines Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546474575","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546474575?lang=en_us&edition=fundamental","pubTime":"2025-06-27 20:39","pubTimestamp":1751027940,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. held its Annual General Meeting on June 27, 2025. The proposals included the adoption of the audited consolidated financial statements for the year ended December 31, 2024, along with the reports from the directors and independent auditor. All proposed resolutions were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL1D2Sns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","01952","BK1161"],"gpt_icon":0},{"id":"2546715297","title":"Zylox-Tonbridge Files Next Day Disclosure Return to HKEX: Announces Repurchase of 897,500 Shares at HKD 482,630","url":"https://stock-news.laohu8.com/highlight/detail?id=2546715297","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546715297?lang=en_us&edition=fundamental","pubTime":"2025-06-27 17:19","pubTimestamp":1751015945,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, revealing the repurchase of 897,500 shares at a total cost of HKD 482,630. The repurchased shares are held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL758KYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","02190","BK1583","BK1100"],"gpt_icon":0},{"id":"2546185587","title":"Zai Lab Ltd. Announces Resignation of Joint Company Secretary and Appoints New Authorised Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=2546185587","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546185587?lang=en_us&edition=fundamental","pubTime":"2025-06-27 16:46","pubTimestamp":1751013980,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd. has announced that Ms. Nelly Au-Yeung will resign as a joint company secretary and authorised representative effective June 27, 2025. Mr. Frazor Titus Edmondson III will become the sole company secretary, and he has also been appointed as an authorised representative starting on the same date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL4ygJzV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","LU2488822045.USD","BK1161","09688","BK1574"],"gpt_icon":0},{"id":"2546083734","title":"Immunotech Biopharm Ltd. Appoints Mr. Yang Xin and Mr. Liu Rui as Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2546083734","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546083734?lang=en_us&edition=fundamental","pubTime":"2025-06-26 22:48","pubTimestamp":1750949284,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm Ltd. has announced the appointment of new directors effective June 26, 2025. Mr. Yang Xin and Mr. Liu Rui have been appointed as non-executive directors, and Mr. Zhang Guoguang joins the board as well. They will serve until the company's next annual general meeting, where they will be eligible for re-election.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunotech Biopharm Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL4R2ypj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2546733564","title":"JW Cayman Therapeutics Co. Ltd. Held Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546733564","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546733564?lang=en_us&edition=fundamental","pubTime":"2025-06-26 20:42","pubTimestamp":1750941763,"startTime":"0","endTime":"0","summary":"JW  Therapeutics Co. Ltd. held its Annual General Meeting on June 26, 2025. During the meeting, several proposals were put forward and approved. All ordinary resolutions presented at the meeting received the necessary votes for approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDLGdscN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02126","BK1574"],"gpt_icon":0},{"id":"2546787555","title":"Keymed Biosciences Inc. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787555?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:40","pubTimestamp":1750938051,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. held its Annual General Meeting on June 26, 2025. During the meeting, several proposals were presented and approved. These included the re-election of Dr. Bo Chen, Dr. Changyu Wang, and Dr. Gang Xu as executive directors, and the re-election of Mr. Qi Chen, Dr. Min Chuan Wang, and Mr. Yilun Liu as non-executive directors. Additionally, Prof. Xiao-Fan Wang, Prof. Yang Ke, and Mr. Cheuk Kin Stephen Law were re-elected as independent non-executive directors. All proposals were passed by shareholders as ordinary resolutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL4TN60T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02162","BK1574","BK1587","BK1583"],"gpt_icon":0},{"id":"2546905785","title":"Genor Biopharma Delays Financial Reporting Circular Again","url":"https://stock-news.laohu8.com/highlight/detail?id=2546905785","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546905785?lang=en_us&edition=fundamental","pubTime":"2025-06-26 17:40","pubTimestamp":1750930829,"startTime":"0","endTime":"0","summary":"Genor Biopharma Holdings Ltd. has announced a further delay in the dispatch of its circular related to several key transactions, including a very substantial acquisition and a proposed merger. The delay pertains to the financial reporting for the period ending December 2024. The announcement does not specify the form type for the delayed financial report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL2tQgf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genor Biopharma Delays Financial Reporting Circular Again","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","06998","BK1574"],"gpt_icon":0},{"id":"2546885827","title":"Kintor Pharmaceutical Ltd: DR. Youzhi Tong Has Stepped Down as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2546885827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546885827?lang=en_us&edition=fundamental","pubTime":"2025-06-26 17:06","pubTimestamp":1750928782,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nFWN3SS0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2546200398","title":"Kintor Pharmaceutical Ltd. Announces New Leadership for Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2546200398","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546200398?lang=en_us&edition=fundamental","pubTime":"2025-06-26 17:02","pubTimestamp":1750928552,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. has announced changes to its Nomination Committee effective June 26, 2025. Dr. Youzhi Tong has stepped down as chairman and member of the committee. Ms. Geqi Wei has been appointed as a member, and Dr. Michael Min Xu is now the chairman. The committee now includes two independent non-executive directors and one non-executive director, enhancing its diversity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL4Vw6C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2546202980","title":"Genor Biopharma Holdings Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546202980","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546202980?lang=en_us&edition=fundamental","pubTime":"2025-06-26 16:39","pubTimestamp":1750927196,"startTime":"0","endTime":"0","summary":"Genor Biopharma Holdings Ltd. held its annual general meeting on June 26, 2025. During the meeting, all proposed resolutions were approved. These included the retirement of Dr. Lyu Dong as a non-executive director and a change in the composition of the board committee, with Mr. Chen Wen appointed as the chairman of the Nomination Committee, and Mr. Fung Edwin and Ms. Cui Bai as members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL5hhs8L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","BK1574","06998"],"gpt_icon":0},{"id":"2546614277","title":"RemeGen Grants Development, Sale Rights to Vor Biopharma for Myasthenia Gravis Drug; Shares Plunge 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546614277","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546614277?lang=en_us&edition=fundamental","pubTime":"2025-06-26 12:43","pubTimestamp":1750912987,"startTime":"0","endTime":"0","summary":"RemeGen  signed a license agreement with Vor Biopharma for the development and sale of Telitacicept worldwide except in Greater China, according to a Thursday filing with the Hong Kong bourse.The license will allow Vor Bio to sell the recombinant B-cell lymphocyte stimulator drug, which is indicated for myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, the filing said.RemeGen and its subsidiary Yantai Rongpu Investment Partnership will receive up to $125 million in consideration from Vor Bio.Vor Bio will also issue $80 million in warrants to Yantai Rongpu in exchange for 320 million common shares in Vor Bio or 23% of the enlarged issued share capital, the filing said.RemeGen will be eligible for an upfront payment of $45 million as well as up to $4.11 billion in milestone payments across several potential indications, and high single-digit to double-digit percentages of actual annual net sales, the filing said.Shares plunge 17% in Hong Kong and Shanghai during ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK0239","LU2488822045.USD","LU1064130708.USD","LU2328871848.SGD","688331","09995","BK1583","LU2148510915.USD","BK1574","LU1969619763.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2546747842","title":"Lu Thai Textile Books 81 Million Yuan Profit From RemeGen Stake Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2546747842","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546747842?lang=en_us&edition=fundamental","pubTime":"2025-06-26 11:44","pubTimestamp":1750909478,"startTime":"0","endTime":"0","summary":"Lu Thai Textile Co (SHE:000726) booked a profit of 81.0 million yuan from the sale of part of its stake in RemeGen (SHA:688331, HKG:9995).The divestment aims to boost liquidity and fund operations, according to a Thursday filing with the Shenzhen bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0028","09995","000726","BK0247","BK0012","BK1574","LU2148510915.USD","BK0239","688331","LU1969619763.USD","LU2488822045.USD","BK1161","BK0188","LU1064130708.USD","BK1583","LU1064131003.USD"],"gpt_icon":0},{"id":"2546222098","title":"CARsgen Therapeutics Announces Nda Acceptance of Satri-Cel by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2546222098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546222098?lang=en_us&edition=fundamental","pubTime":"2025-06-26 08:15","pubTimestamp":1750896903,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA6Y68FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1574","BK1585","02171"],"gpt_icon":0},{"id":"2546222142","title":"CARsgen Therapeutics' New Drug Application for Satricabtagene Autoleucel for Advanced Gastric Cancer Accepted by National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2546222142","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546222142?lang=en_us&edition=fundamental","pubTime":"2025-06-26 08:05","pubTimestamp":1750896354,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics' New Drug Application for Satricabtagene Autoleucel for Advanced Gastric Cancer Accepted by National Medical Products Administration. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL9RG76N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1585","BK1574","BK1587","BK1161"],"gpt_icon":0},{"id":"2546422293","title":"CARsgen Therapeutics  - Nmpa Accepted New Drug Application for Satricabtagene Autoleucel for Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2546422293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546422293?lang=en_us&edition=fundamental","pubTime":"2025-06-26 08:01","pubTimestamp":1750896067,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nFWN3SS0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1585","02171","BK1161","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}